TET2, tumor control, and CAR T cell hyperproliferation.
- Resource Type
- Academic Journal
- Authors
- Dash B; La Jolla Institute for Immunology, La Jolla, CA, USA.; Hogan PG; La Jolla Institute for Immunology, La Jolla, CA, USA; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Program in Immunology, University of California San Diego, La Jolla, CA, USA. Electronic address: phogan@lji.org.
- Source
- Publisher: Cell Press Country of Publication: United States NLM ID: 101665956 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-8025 (Electronic) Linking ISSN: 24058025 NLM ISO Abbreviation: Trends Cancer Subsets: MEDLINE
- Subject
- Language
- English
A recent study by Jain et al. published in Nature followed up on evidence suggesting that depletion of 5-methylcytosine dioxygenase TET2 in chimeric antigen receptor CAR T cells could enhance their expansion, persistence, and antitumor efficacy. Their findings are cautionary, but offer hope of a path forward.
Competing Interests: Declaration of interests P.G.H. is a founder of CalciMedica Inc. and serves on its Scientific Advisory Board. B.D. declares no conflicts of interest.
(Copyright © 2023 Elsevier Inc. All rights reserved.)